Hospital
Flagstaff Medical Center
Flagstaff Medical Center was paid $63.33M by Medicaid between Jan 2018 and Dec 2024, across 355 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoFLAGSTAFF MEDICAL CENTER
FLAGSTAFF, AZ 86001
FLAGSTAFF, AZ 86001
33aNPI1780635078assigned 05/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$63.33M
24GClaims1,153,380
24DCodes billed355
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#7 of 78
Median peer was paid$12.21M
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,930 | $9.85M | |
| 2019 | 191,483 | $10.85M | |
| 2020 | 164,170 | $9.26M | |
| 2021 | 161,432 | $8.26M | |
| 2022 | 153,382 | $8.46M | |
| 2023 | 160,494 | $8.67M | |
| 2024incomplete | 131,489 | $7.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 42,925 | 35,285 | $12.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 23,345 | 20,155 | $9.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 34,568 | 31,639 | $9.20M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 7,703 | 7,229 | $6.62M |
| G0378 | Hospital observation service, per hour | 7.5% | 38,411 | 24,423 | $4.73M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 6.1% | 7,570 | 4,325 | $3.89M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 4,123 | 3,915 | $1.80M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 10,631 | 9,520 | $1.47M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.3% | 3,807 | 3,579 | $1.47M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 2.0% | 831 | 767 | $1.24M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.8% | 4,692 | 4,520 | $1.16M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 10,350 | 9,877 | $1.02M |
343 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,481 | $992K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,889 | $679K |
| 70498 | <1% | 850 | $557K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 23,085 | $480K |
| 94726 | <1% | 957 | $380K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,321 | $363K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,727 | $317K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,197 | $254K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,438 | $239K |
| 97597 | <1% | 1,868 | $234K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,073 | $222K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 861 | $207K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,564 | $200K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 269 | $160K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 67 | $141K |
| 95812 | <1% | 751 | $117K | |
| 47563 | <1% | 25 | $108K | |
| 49083 | <1% | 309 | $106K | |
| 12001 | <1% | 936 | $97K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 17,064 | $95K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 471 | $83K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 109 | $79K |
| 70486 | <1% | 1,450 | $79K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,193 | $78K |
| 97161 | <1% | 6,508 | $73K | |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | <1% | 54 | $72K |
| 59025 | Fetal non-stress test | <1% | 2,321 | $71K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,647 | $67K |
| 92526 | <1% | 1,118 | $65K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,734 | $61K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,628 | $55K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,141 | $54K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,922 | $54K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,615 | $50K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 742 | $48K |
| 87507 | <1% | 153 | $48K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,755 | $45K |
| 80053 | Comprehensive metabolic panel | <1% | 49,834 | $43K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 162 | $42K |
| 72141 | <1% | 77 | $40K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,186 | $35K |
| 77336 | <1% | 434 | $31K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,910 | $30K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,796 | $30K |
| 72170 | <1% | 423 | $28K | |
| 92587 | <1% | 136 | $28K | |
| 12002 | <1% | 439 | $28K | |
| 97162 | <1% | 2,906 | $27K | |
| 97803 | <1% | 1,036 | $27K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,823 | $27K |
| 12011 | <1% | 328 | $26K | |
| 73700 | <1% | 97 | $26K | |
| 87641 | <1% | 4,250 | $25K | |
| 77012 | <1% | 29 | $24K | |
| 88342 | <1% | 813 | $24K | |
| 93971 | <1% | 1,448 | $24K | |
| 77334 | <1% | 53 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 374 | $21K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 12 | $21K |
| 97760 | <1% | 575 | $19K | |
| 88304 | <1% | 1,651 | $19K | |
| J3490 | Unclassified drugs | <1% | 9,767 | $19K |
| S9451 | Exercise classes, non-physician provider, per session | <1% | 929 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,199 | $17K |
| 97116 | <1% | 5,850 | $16K | |
| 72100 | <1% | 946 | $16K | |
| 70496 | <1% | 385 | $15K | |
| 74174 | <1% | 14 | $14K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 969 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,996 | $13K |
| 10060 | <1% | 95 | $13K | |
| 90715 | <1% | 2,911 | $13K | |
| 73221 | <1% | 79 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,440 | $13K |
| 73610 | <1% | 2,154 | $12K | |
| 62323 | <1% | 29 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,121 | $12K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $12K |
| 74018 | <1% | 970 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 61,497 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,367 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,485 | $10K |
| 76770 | <1% | 266 | $9K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 4,076 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,983 | $9K |
| 93976 | <1% | 980 | $9K | |
| 76942 | <1% | 1,168 | $8K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 180 | $8K |
| 73030 | <1% | 2,053 | $8K | |
| 87070 | <1% | 1,567 | $8K | |
| 92588 | <1% | 29 | $8K | |
| 71250 | <1% | 92 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,970 | $8K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 247 | $8K |
| 92523 | <1% | 70 | $7K | |
| 36430 | <1% | 14 | $7K | |
| 73502 | <1% | 718 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,273 | $7K |
| 92585 | <1% | 12 | $7K | |
| 73562 | <1% | 2,001 | $7K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 19 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 76,338 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 347 | $6K |
| 87040 | <1% | 3,098 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,222 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,856 | $6K |
| 73110 | <1% | 1,249 | $6K | |
| 97802 | <1% | 179 | $6K | |
| 87088 | <1% | 9,478 | $6K | |
| 73630 | <1% | 1,493 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 94 | $5K |
| 72131 | <1% | 24 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,219 | $5K |
| 84484 | <1% | 14,491 | $5K | |
| 72040 | <1% | 252 | $5K | |
| 83690 | <1% | 17,027 | $5K | |
| 97113 | <1% | 179 | $5K | |
| 97166 | <1% | 249 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,415 | $5K |
| 73130 | <1% | 1,704 | $5K | |
| 92557 | <1% | 52 | $5K | |
| 0450 | Emergency room services | <1% | 120 | $4K |
| 92567 | <1% | 778 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,226 | $4K |
| 85652 | <1% | 957 | $4K | |
| 85730 | <1% | 5,793 | $4K | |
| 94060 | <1% | 567 | $3K | |
| 96111 | <1% | 164 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,252 | $3K |
| 93308 | <1% | 100 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,802 | $3K |
| 83880 | <1% | 4,565 | $3K | |
| 97163 | <1% | 58 | $3K | |
| 92610 | <1% | 143 | $3K | |
| 96112 | <1% | 76 | $3K | |
| 82803 | <1% | 2,069 | $3K | |
| 83605 | <1% | 11,584 | $3K | |
| 92552 | <1% | 85 | $3K | |
| 74230 | <1% | 13 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 944 | $3K |
| 81025 | <1% | 10,053 | $3K | |
| 29125 | <1% | 364 | $3K | |
| 97165 | <1% | 1,109 | $2K | |
| 97542 | <1% | 71 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 68 | $2K |
| 82607 | <1% | 262 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,272 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,282 | $2K |
| 76801 | <1% | 546 | $2K | |
| 85379 | <1% | 3,320 | $2K | |
| 80061 | Lipid panel | <1% | 1,792 | $2K |
| 97164 | <1% | 75 | $2K | |
| 84703 | <1% | 6,670 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,891 | $2K |
| 87077 | <1% | 2,544 | $2K | |
| 86900 | <1% | 5,591 | $2K | |
| 92553 | <1% | 30 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,586 | $2K |
| 84439 | <1% | 938 | $2K | |
| 92593 | <1% | 122 | $2K | |
| 99152 | <1% | 293 | $2K | |
| 80329 | <1% | 3,364 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 89 | $2K |
| 81001 | <1% | 17,222 | $1K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 28 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 12 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 67 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 836 | $1K |
| 73080 | <1% | 335 | $1K | |
| 99245 | <1% | 30 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,420 | $1K |
| 82962 | <1% | 16,742 | $1K | |
| 82140 | <1% | 564 | $1K | |
| 88341 | <1% | 75 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 248 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,107 | $1K |
| 92579 | <1% | 55 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,996 | $1K |
| 73560 | <1% | 89 | $1K | |
| 82728 | <1% | 178 | $1K | |
| 90839 | <1% | 234 | $1K | |
| 73590 | <1% | 604 | $1K | |
| 85610 | <1% | 12,189 | $1K | |
| 83735 | <1% | 10,689 | $1K | |
| 84702 | <1% | 2,127 | $1K | |
| 86141 | <1% | 2,019 | $1K | |
| 93970 | <1% | 42 | $1K | |
| 77300 | <1% | 54 | $980.54 | |
| A9270 | Non-covered item or service | <1% | 8,690 | $916.07 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $878.48 |
| 73140 | <1% | 404 | $853.13 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 27 | $818.39 |
| 88307 | <1% | 349 | $806.78 | |
| 87186 | <1% | 2,249 | $770.13 | |
| 77002 | <1% | 14 | $745.74 | |
| 80320 | <1% | 7,780 | $721.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,658 | $707.86 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,085 | $635.42 |
| 86850 | <1% | 4,783 | $635.02 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,906 | $633.42 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 15 | $624.02 |
| 87631 | <1% | 840 | $583.57 | |
| C9399 | Unclassified drugs or biologicals | <1% | 353 | $581.59 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,794 | $578.81 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,555 | $574.46 |
| 64415 | <1% | 29 | $558.08 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,233 | $541.05 |
| 96376 | <1% | 5,103 | $504.20 | |
| 82550 | <1% | 3,327 | $499.57 | |
| 51798 | <1% | 1,182 | $468.86 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 154 | $466.29 |
| 81003 | <1% | 9,743 | $461.24 | |
| 73070 | <1% | 180 | $442.44 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,719 | $405.47 |
| 84145 | <1% | 1,573 | $399.34 | |
| 73564 | <1% | 45 | $383.04 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,905 | $382.87 |
| 84100 | <1% | 5,171 | $372.18 | |
| 97014 | <1% | 756 | $349.55 | |
| 82150 | <1% | 1,450 | $345.41 | |
| 87486 | <1% | 914 | $325.78 | |
| 94760 | <1% | 3,319 | $320.94 | |
| 73090 | <1% | 515 | $312.11 | |
| 87581 | <1% | 914 | $300.38 | |
| 12013 | <1% | 15 | $292.59 | |
| 87480 | <1% | 391 | $291.96 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,749 | $291.31 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,584 | $258.23 |
| 85027 | <1% | 4,165 | $245.72 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,506 | $237.23 |
| 86901 | <1% | 4,149 | $221.70 | |
| 87149 | <1% | 394 | $220.73 | |
| 86140 | <1% | 162 | $218.90 | |
| 87660 | <1% | 392 | $217.70 | |
| 73620 | <1% | 17 | $199.51 | |
| 74022 | <1% | 55 | $179.01 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,967 | $167.34 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,848 | $144.94 |
| 82330 | <1% | 286 | $138.44 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 975 | $133.84 |
| 72070 | <1% | 12 | $124.83 | |
| 87205 | <1% | 1,500 | $111.71 | |
| 82247 | <1% | 30 | $110.70 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15 | $103.90 |
| 90686 | <1% | 412 | $102.24 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 955 | $101.26 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,850 | $101.04 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,982 | $100.20 |
| 73600 | <1% | 28 | $76.38 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 542 | $73.01 |
| 97032 | <1% | 48 | $69.66 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,871 | $69.29 |
| 87075 | <1% | 790 | $68.25 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 71 | $64.54 |
| 97035 | <1% | 25 | $62.40 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 471 | $61.83 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,363 | $60.58 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,526 | $59.27 |
| 73552 | <1% | 14 | $58.98 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 811 | $58.56 |
| 94729 | <1% | 952 | $58.23 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 344 | $57.23 |
| 99243 | <1% | 12 | $54.80 | |
| 82010 | <1% | 474 | $50.63 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,646 | $49.96 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,246 | $48.74 |
| 36600 | <1% | 123 | $47.26 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,180 | $39.88 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 140 | $34.12 |
| 0358T | <1% | 49 | $31.75 | |
| 94799 | <1% | 105 | $30.34 | |
| C1769 | Guide wire | <1% | 367 | $26.12 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 439 | $22.79 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 389 | $22.10 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 693 | $20.97 |
| 89051 | <1% | 252 | $20.05 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,189 | $15.94 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 50 | $15.66 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 96 | $13.92 |
| 76882 | <1% | 15 | $9.45 | |
| 84132 | <1% | 15 | $9.24 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 874 | $8.89 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 91 | $7.62 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 78 | $7.48 |
| 83550 | <1% | 165 | $5.51 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $5.02 |
| 88738 | <1% | 473 | $4.72 | |
| 86706 | <1% | 13 | $0.56 | |
| 87340 | <1% | 84 | $0.54 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 5,041 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 39 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 513 | $0.00 |
| 83540 | 0% | 126 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 85 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 50 | $0.00 |
| 96367 | 0% | 16 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 13 | $0.00 |
| 85007 | 0% | 13 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 76 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 463 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 52 | $0.00 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 27 | $0.00 |
| 92550 | 0% | 16 | $0.00 | |
| 77412 | 0% | 266 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 57 | $0.00 |
| 84550 | 0% | 26 | $0.00 | |
| 76376 | 0% | 12 | $0.00 | |
| 51702 | 0% | 31 | $0.00 | |
| 84112 | 0% | 19 | $0.00 | |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | 0% | 28 | $0.00 |
| 93325 | 0% | 12 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 18 | $0.00 |
| 74300 | 0% | 13 | $0.00 | |
| 92611 | 0% | 13 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 116 | $0.00 |
| 93017 | 0% | 13 | $0.00 | |
| 84520 | 0% | 14 | $0.00 | |
| 77387 | 0% | 133 | $0.00 | |
| 29515 | 0% | 13 | $0.00 | |
| 85004 | 0% | 45 | $0.00 | |
| 94770 | 0% | 14 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 204 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 141 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 59 | $0.00 |
| 97016 | 0% | 106 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 25 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 84 | $0.00 |
| 83615 | 0% | 27 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 256 | $0.00 |
| 74019 | 0% | 12 | $0.00 | |
| 96368 | 0% | 24 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 18 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 15 | $0.00 |
| 82945 | 0% | 31 | $0.00 | |
| 85576 | 0% | 18 | $0.00 | |
| 73060 | 0% | 42 | $0.00 | |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 16 | $0.00 |
| 86920 | 0% | 12 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 14 | $0.00 |
| 90656 | 0% | 13 | $0.00 | |
| 87081 | 0% | 31 | $0.00 | |
| 82270 | 0% | 12 | $0.00 | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOFIELD, ROBERT (CHIEF OPERATING OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Flagstaff Medical Center | Flagstaff, AZ | $46.22M |
| Flagstaff Medical Center | Flagstaff, AZ | $37.58M |
| Verde Valley Medical Center | Cottonwood, AZ | $26.43M |
| Northern Arizona Healthcare Corporation | Flagstaff, AZ | $11.37M |
| Northern Arizona Healthcare Corporation | Flagstaff, AZ | $6.03M |
| Verde Valley Medical Center | Sedona, AZ | $1.12M |
| Northern Arizona Healthcare Orthopedic Surgery Center, LLC | Flagstaff, AZ | $354K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.